Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 02 December 2013 | By Alexander Gaffney, RAC
Just days after President Barack Obama signed the Drug Quality and Security Act (DQSA) into law, the US Food and Drug Administration (FDA) has released three draft guidance documents intended to interpret its provisions and provide definitional clarity for compounding pharmacies.
The DQSA contains two sets of measures: One intended to better secure the pharmaceutical supply chain, and the other to more rigorously regulate the compounding pharmacy sector after a series of major lapses in quality.
The legislation creates a voluntary registration system by which compounding facilities can sign up to be inspected by FDA. The hope of legislators is that facilities will have a greater incentive to purchase supplies from these facilities, and in turn incent companies to become registered with FDA in the first place.
The legislation also bans compounders from making "essentially a copy of a marketed and approved drug," and gives FDA new authority to inspect compounding facilities in accordance with a "risk-based schedule." Companies, in turn, will be required to report adverse events to FDA.
However, the bill's compounding provisions mostly leave intact the patchwork of regulations that critics have contended allowed deficient compounding practices to harm patients in the first place. Compounders that continue to operate within state lines will still be regulated by state boards of pharmacy-not FDA.
The bill was signed into law by Obama on Wednesday, 27 November 2013.
The legislation had long been in the works, affording FDA an unusually long lead time to develop guidance. Even then, the release of the guidance just days after the signing of the legislation marks an unusual-perhaps even unprecedented-speed for the agency, which can sometimes take years to release guidance. The agency has been clamoring for more authority with which to confront the compounders since an October 2011 outbreak of fungal meningitis from a Massachusetts-based compounding pharmacy, the New England Compounding Center (NECC), and the speed may reflect its desire to move forward as quickly as possible.
The three draft guidance documents are relatively short, and cover three distinct topics:
The DQSA removed certain provisions from the statute that the court had found to be unconstitutional, and FDA said it was "necessary to explain FDA's current thinking with regard to section 503A."
In Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA explains the conditions under which a compounded product must be produced in order to be exempt from other relevant provisions of federal law.
Specifically, the drug must:
FDA also said drugs may be compounded in "limited quantities" prior to the receipt of a prescription provided it has historically received valid orders for the product.
Regulators also listed several other statutory provisions which they said have not yet gone into full effect. For example, FDA has not yet finalized a list of products which compounders may not create due to demonstrable difficulties in assuring safety or efficacy. Those provisions will not go into effect until a final rule is promulgated.
Compounded drugs will also be subject to quality standards, and a failure to meet those standards will subject the compounder and its products to regulatory enforcement by FDA and federal authorities. FDA said it will in general employ a risk-based enforcement approach.
An earlier 1998 guidance document on compounding has been withdrawn.
A second draft guidance, Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act, reflects a new category of "outsourcing facilities" under the DQSA.
Such facilities will be inspected by FDA regulators more similarly to traditional (i.e. conventional) pharmaceutical manufacturers. Outsourcing facilities must register with FDA annually between 1 October and 31 December and provide to FDA a list of all products they intend to compound in the next year, and drugs on FDA's shortage list, and whether they compound sterile drugs or drugs in bulk. In addition, companies need to provide information about the location and mailing address of each facility, as well as a unique facility identifier.
Companies who elect to register should be compounders of sterile drugs, FDA said.
A third draft guidance document, Interim Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act, is also intended to outline the requirements for outsourcing facilities. In particular, the guidance clarifies that outsourcing facilities under 503B of the FD&C Act must submit to FDA a list of all drug products compounded by the facility during the previous six-month period. The list must be submitted twice per year, in June and December.
Each submission must contain specific information.
Reports should be made through FDA's electronic drug registration and listing service in structured product labeling (SPL) format.
Tags: Drug Quality and Security Act, DQSA, Pharmaceutical Compounding, Compounding, Legislation, Latest News, draft guidance